FORT LAUDERDALE, Fla.

佛罗里达州劳德代尔堡

,

，

July 7, 2026

2026年7月7日

/PRNewswire/ -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited

/美通社/ -- Splash Beverage Group, Inc.（纽约证券交易所美国市场股票代码：SBEV）今日宣布，已与Argent BioPharma Limited达成一项独家全球许可协议

(ASX: RGT) (LSE: RGT)

（澳大利亚证券交易所：RGT）（伦敦证券交易所：RGT）

for CannEpil

用于CannEpil

®

®

, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.

，一种专有、受专利保护的基于大麻素的 investigational 治疗药物，已在多个欧洲国家获批用于治疗耐药性癫痫（DRE）。

CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including Ireland, the United Kingdom, Germany and Australia. The therapy is manufactured under European Union Good Manufacturing Practice (EU-GMP) standards and benefits from an existing international distribution infrastructure..

CannEpil 是一种药用级大麻素疗法，已获准在包括爱尔兰、英国、德国和澳大利亚在内的多个国际市场销售。该疗法按照欧盟药品生产质量管理规范（EU-GMP）标准生产，并依托现有的国际分销基础设施进行推广。

Drug-resistant epilepsy affects approximately 30% of epilepsy patients worldwide and remains one of the most significant unmet needs in neurology, with millions of patients continuing to experience uncontrolled seizures despite currently available therapies.

耐药性癫痫影响全球约30%的癫痫患者，仍然是神经病学领域最显著且未满足的需求之一，尽管现有疗法可用，仍有数百万患者持续经历无法控制的癫痫发作。

'Acquiring exclusive global rights to CannEpil represents a transformational milestone for Splash and provides us with a unique opportunity to participate in one of the most attractive specialty neurology markets in healthcare,' said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group..

Splash Beverage Group 临时首席执行官 Brady Cobb 表示：“获得 CannEpil 的全球独家权利对 Splash 而言是一个具有变革意义的里程碑，为我们提供了参与医疗保健领域最具吸引力的专科神经市场之一的独特机会。”

'What attracted us to CannEpil is that this is not an early-stage laboratory asset. CannEpil has already been prescribed through regulated patient-access programs, has established reimbursement-supported access in Europe, has generated meaningful real-world patient experience and has already engaged with the FDA regarding its U.S.

“吸引我们关注 CannEpil 的原因在于，它并非处于早期阶段的实验室资产。CannEpil 已通过受监管的患者 access 项目获得处方使用，在欧洲建立了有报销支持的可及性，积累了具有意义的真实世界患者使用经验，并已就其在美国的上市事宜与美国食品药品监督管理局（FDA）展开沟通。”

development pathway. We believe the combination of existing international utilization, regulatory progress and the significant unmet need in drug-resistant epilepsy creates a compelling opportunity to substantially build revenue and long-term shareholder value.'.

发展路径。我们认为，现有的国际化应用、监管进展以及耐药性癫痫领域巨大的未满足需求相结合，创造了令人信服的机会，能够显著提升收入并创造长期的股东价值。

CannEpil has achieved important commercial and regulatory milestones internationally. In Ireland, the therapy became eligible under the country's Medicinal Cannabis Access Program (MCAP) and is supported through reimbursement mechanisms administered by Ireland's Health Service Executive (HSE). In the United Kingdom, CannEpil has been authorized for importation and prescription through the Named Patient Request framework and has been utilized through specialist treatment pathways serving patients with severe treatment-resistant epilepsy..

CannEpil 在国际上取得了重要的商业和监管里程碑。在爱尔兰，该疗法已纳入该国的医用大麻访问计划（MCAP），并通过爱尔兰卫生服务执行局（HSE）管理的报销机制获得支持。在英国，CannEpil 已通过“指定患者申请”框架获准进口和处方，并经由针对严重难治性癫痫患者的专科治疗路径得到应用。

The program has also initiated formal engagement with the U.S. Food and Drug Administration through the pre-IND process and has been assigned an Investigational New Drug (IND) number, providing a foundation for future U.S. clinical development.

该项目已通过pre-IND流程与美国食品药品监督管理局（FDA）展开正式沟通，并获分配研究性新药（IND）编号，为未来在美国的临床开发奠定了基础。

As part of the transaction, Splash has secured a $1 million strategic investment commitment from C/M Capital Partners to support regulatory advancement, clinical development planning, commercialization initiatives and strategic partnership activities designed to accelerate the development of CannEpil in the United States and other key markets..

作为交易的一部分，Splash已获得C/M Capital Partners提供的100万美元战略投资承诺，用于支持监管推进、临床开发规划、商业化举措以及旨在加速CannEpil在美国及其他关键市场开发的战略合作活动。

Splash intends to deploy proceeds from the strategic investment toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging leading U.S. epilepsy investigators and identifying a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials..

Splash 计划将战略投资所得资金用于推进与 FDA 相关的工作，扩充现有的临床和真实世界证据组合，与美国领先的癫痫研究人员合作，并确定一家能够支持未来在美国开展的临床试验的战略合作伙伴。

TRANSACTION DETAILS

交易详情

Under the terms of the agreement, Splash has acquired exclusive worldwide rights to develop, commercialize, market, distribute, sublicense and sell CannEpil

根据协议条款，Splash已获得开发、商业化、市场推广、分销、再许可及销售CannEpil的独家全球权利。

®

®

for the treatment of drug-resistant epilepsy, refractory epilepsy, seizure disorders and related neurological conditions.

用于治疗耐药性癫痫、难治性癫痫、癫痫发作及相关神经系统疾病。

The license encompasses all global territories and includes rights to future product improvements, reformulations and next-generation product developments within the licensed field.

该许可涵盖全球所有地区，并包括在许可领域内对未来产品改进、配方调整以及下一代产品开发的权利。

In addition to its affiliate's $1 million capital infusion described above and as  consideration for the transaction, Mercer Street Global Opportunity Fund agreed to forgive approximately $5 million of Argent BioPharma indebtedness and Splash agreed to issue to $5.5 million of newly issued Splash preferred equity as part of the consideration for the license, aligning stakeholders behind the future development and commercialization of the CannEpil platform..

除了上述关联方的100万美元资本注入以及作为交易对价外，Mercer Street Global Opportunity Fund同意免除Argent BioPharma约500万美元的债务，Splash同意发行价值550万美元的新增Splash优先股权，作为许可协议对价的一部分，从而使各方利益相关者在CannEpil平台的未来开发和商业化方面保持一致。

Argent BioPharma is incentivized to continue to participate in the long-term success of the program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.

Argent BioPharma 通过获得相当于 CannEpil 全球销售净收入 15% 的特许权使用费，被激励继续参与该计划的长期成功。

The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term and includes rights to sublicense the technology to strategic pharmaceutical partners globally.

该协议授予Splash在初始二十年内独占性的全球商业化权利，并包含向全球战略性制药合作伙伴分许可该技术的权利。

About Splash Beverage Group, Inc.

关于 Splash Beverage Group, Inc.

Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building initiatives..

Splash Beverage Group, Inc.（纽交所美国市场：SBEV）是一家总部位于佛罗里达州劳德代尔堡的上市公司。公司正通过审慎的资本配置、战略投资、收购以及其他平台构建举措，推进向大麻素健康、 wellness 及生物制药平台的战略转型。

More Information

更多信息

Splash Beverage Group

飞溅饮料集团

Contact Information

联系方式

Splash Beverage Group

Splash Beverage Group

[email protected]

[email protected]

Media Contact

媒体联系人

Angela Gorman

安吉拉·戈尔曼

AMWPR

AMWPR

[email protected]

[email protected]

917-348-0083

917-348-0083

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's acquisition of an exclusive worldwide license to CannEpil and the intended uses and benefits of the license including its potential to substantially build revenue and long-term shareholder value, long-term shareholder value, the potential prospects and demand for the licensed product, progress and plans with respect to the development and commercialization of the product, and C/M Capital's commitment to invest $1 million to support the development of the program.

本新闻稿包含经1995年《私人证券诉讼改革法》界定的前瞻性陈述，包括有关公司获得CannEpil独家全球许可的陈述，以及该许可的预期用途和益处（包括其在大幅增加收入和长期股东价值方面的潜力）、许可产品的潜在前景和需求、与产品开发和商业化相关的进展和计划，以及C/M Capital承诺投资100万美元以支持该项目开发的陈述。

and the perceived or anticipated benefits and prospects thereof Forward-looking statements are prefaced by words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'may,' 'will,' 'should,' 'would,' 'intend,' 'potential,' 'believe,' 'estimate,' 'forecast,' 'project,' and similar words..

以及其感知或预期的利益和前景。前瞻性陈述通常以“预期”、“期望”、“计划”、“能够”、“可能”、“将”、“应该”、“会”、“打算”、“潜在”、“相信”、“估计”、“预测”、“规划”等词语作为前缀，以及类似用语。

Forward-looking statements are based on current expectations and assumptions regarding the Company's business and future conditions and are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Actual results may differ materially from those contemplated by such forward-looking statements due to a variety of factors, including, without limitation, the possibility that the license does not yield the benefits anticipated or sought, our ability to raise the capital necessary to develop and commercialize the product and otherwise meet our working capital needs, our need to comply with extensive regulations including clinical testing before we can market the product in applicable jurisdictions including the U.S., the possibility that a market for the product does not develop to the extent anticipated or projected, and the status of evolving regulatory conditions within the cannabinoid and wellness industries..

前瞻性陈述基于对公司业务及未来状况的当前预期和假设，并受限于固有的不确定性、风险以及难以预测的环境变化。由于多种因素，实际结果可能与这些前瞻性陈述所预期的存在重大差异，包括但不限于：许可未能产生预期或寻求的收益；我们筹集开发和产品商业化所需资金以及满足其他营运资金需求的能力；在包括美国在内的适用司法管辖区销售产品前，我们需要遵守包括临床试验在内的广泛监管要求；产品市场未能按预期或预测发展的可能性；以及大麻素和大健康行业不断演变的监管环境的状态。

Additional information concerning these and other risk factors is contained in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Final Prospectus on Form 424B3 filed on June 26, 2026. Any forward-looking statement made by the Company speaks only as of the date on which it is made.

有关这些及其他风险因素的更多信息，请参阅本公司向美国证券交易委员会提交的文件，包括截至2025年12月31日止年度的10-K表格年度报告以及于2026年6月26日提交的424B3表格最终招股说明书。本公司作出的任何前瞻性陈述仅在其作出之日有效。

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law..

除法律要求外，本公司不承担公开更新任何前瞻性陈述的义务，无论该等更新是由于新信息、未来发展或其他原因所致。

SOURCE Argent BioPharma Ltd.

来源：Argent BioPharma Ltd.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示